Lambda Biologics GmbH, headquartered in the Leipzig Bio Cluster in Germany and led by CEO André Gerth, is advancing the future of preclinical testing with a focus on organoid-based solutions. As a growing biohealth testing platform, Lambda combines accurate in vitro testing with a commitment to improving research workflows. Beyond delivering test results, the company serves as a knowledge hub, helping researchers work more efficiently and with greater precision.
In October 2024, Lambda Biologics received public funding from the Free State of Saxony, supported by the European Union. This grant is dedicated to accelerating the development of Advanced Therapy Medicinal Products (ATMPs), including gene therapies, cell therapies, and tissue-engineered treatments. It reflects regional and EU-level confidence in Lambda’s potential to deliver scalable, human-relevant medical innovations.
A Strategic Partnership for Organoid-Based Therapeutics
To move this mission forward, Lambda has partnered with OrganoidSciences, led by CEO Jongman Yoo. Known for its leadership in organoid technology, OrganoidSciences received ATMP certification from the European Medicines Agency (EMA) in 2023 for its therapeutic candidate, ATORM-C. This organoid-based therapy targets refractory intestinal ulcers by promoting tissue regeneration.
ATMPs, including gene therapies, cell therapies, and tissue-engineered products, offer promising alternatives to traditional pharmaceuticals. Germany’s advanced medical infrastructure and supportive regulatory framework create favorable conditions for developing and commercializing these therapies.
The regulatory environment in Germany supports faster patient access through mechanisms like the Hospital Exemption pathway. This allows more rapid clinical application of ATMPs compared to conventional drug approval routes. In addition, strong collaboration among academia, biotech companies, and regulatory authorities helps secure resources and enables the launch of large-scale clinical trials across Europe.
European public funding also opens the door to follow-on investment and equity capital of more than €15 million after the initial funding phase. With this support, Lambda Biologics plans to expand its R&D efforts throughout Europe, working in close partnership with OrganoidSciences. Together, they are advancing the future of regenerative medicine and contributing to the continued growth of the European biotech sector.
